Jinlin Song
 
                    Education
Ph.D., applied mathematics, University of Southern California; M.S., statistics, University of Southern California; B.S., applied mathematics, Shanghai Jiaotong University
Summary of Experience
Dr. Song specializes in health economics and outcomes research (HEOR). She has extensive experience applying advanced statistical techniques to solve complex real-world research questions in health care, frequently using data from clinical trials, electronic medical records, administrative claims, medical chart reviews, surveys, and disease registries. Dr. Song has conducted indirect treatment comparisons such as network meta-analyses and matching-adjusted indirect comparisons, as well as economic modeling such as cost-effectiveness analyses and budget impact analyses. Her research covers a broad range of therapeutic areas – including endocrinology, oncology, hematology, nephrology, infectious diseases, autoimmune diseases, and rare genetic diseases – and involves assessing burden of illness, treatment patterns, and drug adherence; performing systematic literature reviews; and conducting studies evaluating real-world economic and clinical outcomes. Dr. Song has developed strategic plans for real-world evidence generation and supported the launch of multiple novel oncology products, including targeted therapies, immuno-oncology agents, and gene therapies. Her work has been widely published in peer-reviewed journals and presented at clinical and economic research conferences.
- 
                                                        Cytochrome P450 inhibitor/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors in the first-line maintenance settingGynecologic Oncology Reports, 2024 
 2024Rimel BJ, Chase DM, Perhanidis J, Ghazarian AA, Du EX, Wang T, Song J, Golembesky AK, Hurteau JA, Kalilani L, Salani R, Monk BJ 
- 
                                                        Treatment Patterns and Resource Use After Osimertinib Discontinuation in Patients with EGFR + Metastatic NSCLCOncology and Therapy, 2024 
 2024
- 
                                                        Comparative Efficacy of Venetoclax-Based Combination Therapies and Other Therapies in Treatment-Naive Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy: A Network Meta-AnalysisValue in Health, 2023 
 2023Li X, Suh HS, Lachaine J, Schuh AC, Pratz K, Betts KA, Song J, Dua A, Bui CN 
- 
                                                        Treating Anemic Patients With Myelofibrosis in the New Janus Kinase Inhibitor Era: Current Evidence and Real-world ImplicationsHemaSphere, 2022 
 2022Gerds AT, Bose P, Hobbs GS, Kuykendall AT, Neilson LM, Song J, Klencke B, Harrison CN 
- 
                                                        Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapyJournal of Managed Care & Specialty Pharmacy, 2022 
 2022Choi M, Song J, Bui CN, Ma E, Chai X, Yin L, Betts KA, Kapustyan T, Montez M, LeBlanc TM 
- 
                                                        CKD Progression and Economic Burden in Individuals with CKD Associated with Type 2 DiabetesKidney Medicine, 2022 
 2022Mullins CD, Pantalone KM, Betts KA, Song J, Wu A, Chen Y, Kong SX, Singh R 
- 
                                                        Network meta-analysis of nivolumab plus ipilimumab in the second-line setting for advanced hepatocellular carcinomaJournal of Comparative Effectiveness Research, 2021 
 2021Parikh ND, Marshall A, Betts KA, Song J, Zhao J, Yuan M, Wu A, Huff KD, Kim R 
- 
                                                        Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell LymphomaClinical Therapeutics, 2019 
 2019Telford C, Kabadi SM, Abhyankar S, Song J, Signorovitch J, Zhao J, Yao Z 
- 
                                                        Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic LeukemiaAdvances in Therapy, 2019 
 2019Song J, Ma Q, Gao W, Cong Z, Xie J, Zimmerman Z, Belton L, Franklin J, Palmer S 
- 
                                                        Epilepsy treatment patterns among patients with tuberous sclerosis complexJournal of the Neurological Sciences. 2018 Aug 15;391:104-108 
 2018Song J, Swallow E, Said Q, Peeples M, Meiselbach M, Signorovitch J, Kohrman M, Korf B, Krueger D, Wong M, Sparagana S 
- 
                                                        Patterns of Disease Monitoring and Treatment Among Patients With Tuberous Sclerosis Complex-related AngiomyolipomasUrology. Jun 2017;104:110-114 
 2017Swallow E, King S, Song J, Peeples M, Signorovitch JE, Liu Z, Prestifilippo J, Frost M, Kohrman M, Korf B, Krueger D, Sparagana S 
- 
                                                        Real-World Outcomes of Acute Ischemic Stroke Treatment with Intravenous Recombinant Tissue Plasminogen ActivatorJournal of Stroke and Cerebrovascular Diseases. Sep 2017;26(9):1996-2003 
 2017Betts KA, Hurley D, Song J, Sajeev G, Guo J, Du EX, Paschoalin M, Wu EQ 
- 
                                                        Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect ComparisonRheumatology Therapeutics. Jul 31 2017 
 2017
- 
                                                        Patterns of Disease Monitoring and Treatment Among Patients with Tuberous Sclerosis Complex-related (1)Urology. Jun 2017;104:110-114 
 2017Swallow E, King S, Song J, Peeples M, Signorovitch JE, Liu Z, Prestifilippo J, Frost M, Kohrman M, Korf B, Krueger D, Sparagana S 
- 
                                                        Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophyNeuromuscuarl Disorders, 2016 05. e-pub ahead of print 2016/07/18; doi: 10.1016/j.nmd.2016.05.016. 
 2016Mercuri E, Signorovitch J, Swallow E, Song J, Ward SJ. 
- 
                                                        Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparisonJournal of Comparative Effectiveness Research, 2016 03; 5(2): 129-139. e-pub ahead of print 2015/09/22 
 2016Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Mu F, Kim S, Noviello S, Signorovitch J. 
- 
                                                        Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect ComparisonClinical Therapeutics, 2016 02; 38(2): 404-412. e-pub ahead of print 2016/02/04 
 2016Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Peeples M, Mu F, Ackerman P, Signorovitch J. 
- 
                                                        Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular D(1)PLOS ONE, 2016 Oct 13;11(10):e0164684 
 2016Goemans N, Vanden Hauwe M, Signorovitch J, Swallow E, Song J 
- 
                                                        Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective studyBMC Infectious Diseases, December 1, 2016 
 2016Kontoyiannis DP, Yang H, Song J, Kelkar SS, Yang X, Azie N, Harrington R, Fan A, Lee E, Spalding JR 
